WARMINSTER, Pa., July 29, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its second quarter financial results, conference… Read More
Recent Milestone Demonstrates Continued Progress Across Three Concurrent Studies of VAL-083 in Different Phases of GBM Progression VANCOUVER, British Columbia and MENLO PARK, Calif., July 31, 2019 /PRNewswire/ — DelMar Pharmaceuticals,… Read More
New Study Arm Provides Significant Opportunity for Multiple Applications of VAL-083 Treatment in GBM VANCOUVER, British Columbia and MENLO PARK, Calif., July 24, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar”… Read More
Vancouver, British Columbia – July 23rd, 2019 – Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of microbial-based immunotherapies designed to restore… Read More
Results demonstrate that AB-506 is a potent capsid inhibitor Phase 1a/1b clinical trial to continue with the enrollment of further cohorts Conference call and webcast scheduled today at 4:45 pm ET… Read More
